指南与共识妇科肿瘤

卵巢癌患者BRCA基因检测推荐意见的当前观点

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
指南 / 共识 · Eur J Cancer · 2016-11-04

本文综述欧盟现有数据与指南,重新审视卵巢癌患者BRCA基因检测的转诊标准。建议所有浸润性上皮性卵巢癌(除外交界性或黏液性)患者,无论年龄,均应考虑转诊进行BRCA基因检测,理想情况下在诊断时提供检测。

要点

  • 所有浸润性上皮性卵巢癌(含输卵管癌和腹膜癌)患者,无论年龄,均应考虑转诊进行BRCA基因检测。
  • BRCA基因检测理想情况下应在诊断时提供,但患者可在任何阶段转诊。
  • 长期随访中的患者应提供回顾性检测,因对家庭成员及个体未来乳腺癌风险有影响。

核心结论

  • 所有浸润性上皮性卵巢癌(除外交界性或黏液性),包括输卵管癌和腹膜癌患者,无论年龄,均应考虑转诊进行BRCA基因检测。
  • BRCA基因检测理想情况下应在诊断时提供,但患者可在任何阶段转诊。
  • 长期随访中的患者应提供回顾性检测,因对家庭成员及个体未来乳腺癌风险有影响。
  • 初始应进行血液/唾液样本的胚系BRCA检测,若阴性则检测肿瘤组织以识别非胚系(体细胞)BRCA PARPi治疗候选者。

研究设计与样本

  • 本文为综述,基于欧盟现有数据与指南,审视卵巢癌患者BRCA基因检测的转诊推荐与考量。

主要发现

  • 卵巢癌患者即使无已知家族史,也可能携带BRCA1/2突变。
  • 首个聚腺苷二磷酸核糖聚合酶抑制剂(PARPi;奥拉帕利[Lynparza])已获批用于治疗BRCA突变卵巢癌。

关键数值与推荐

  • 所有浸润性上皮性卵巢癌(除外交界性或黏液性),包括输卵管癌和腹膜癌患者,无论年龄,均应考虑转诊进行BRCA基因检测。
  • BRCA基因检测理想情况下应在诊断时提供,但患者可在任何阶段转诊。
  • 长期随访中的患者应提供回顾性检测。
  • 初始应进行血液/唾液样本的胚系BRCA检测,若阴性则检测肿瘤组织。

临床怎么用

  • 所有浸润性上皮性卵巢癌(除外交界性或黏液性),包括输卵管癌和腹膜癌患者,无论年龄,均应考虑转诊进行BRCA基因检测。
  • BRCA基因检测理想情况下应在诊断时提供,但患者可在任何阶段转诊。
  • 长期随访中的患者应提供回顾性检测。
  • 初始应进行血液/唾液样本的胚系BRCA检测,若阴性则检测肿瘤组织。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now recognised risk of ovarian cancer (OC) patients, even those with no known family history, harbouring a mutation in BRCA1/2, together with the first poly adenosine diphosphate ribose polymerase inhibitor (PARPi; olaparib [Lynparza]) being licenced for the treatment of BRCA-mutated OC, has led to reconsideration of referral criteria for OC patients. Provided here is a review of the existing data and guidelines in the European Union, relating to recommendations, as well as considerations, for the referral of OC patients for BRCA genetic testing. Based on this review of newly updated guidance and up-to-date evidence, the following is recommended: all patients with invasive epithelial OC (excluding borderline or mucinous), including those with fallopian tube and peritoneal cancers, should be considered as candidates for referral for BRCA genetic testing, irrespective of age; genetic testing should ideally be offered at diagnosis, although patients can be referred at any stage; retrospective testing should be offered to patients in long-term follow-up because of the implications for family members and individual future breast cancer risk; and germline BRCA testing of a blood/saliva sample should initially be conducted and, if negative, tumour tissue should be tested (to identify non-germline [somatic] BRCA PARPi therapy candidates).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vergote I, Banerjee S, Gerdes AM, et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016. PMID: 27821315. doi:10.1016/j.ejca.2016.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。